Home »
Academic Articles & Research Papers
Showing 20 of 64 academic articles
Huang L, Wan Y, Yang Z, Zhou Z et al. • Frontiers in immunology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fimmu.2026.1953030
PMC: PMC13617522
Moursi A, Barry A, Feugere L, Iles A et al. • Cancer immunology, immunotherapy : CII
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1007/s00262-026-04486-w
PMC: PMC13620026
He H, Zhang H, Lv H, Wang W • Frontiers in immunology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fimmu.2026.1944032
PMC: PMC13646074
Sun J, Fan Z, Caldino Bohn R, Kim S et al. • Briefings in bioinformatics
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1093/bib/bbag545
PMC: PMC13660471
Park CL, Dinstag G, Lopes CDH, Strum S et al. • NPJ precision oncology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1038/s41698-026-01520-z
PMC: PMC13669336
Wang B, Zhao D, Ma Y, Sui C • Frontiers in immunology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fimmu.2026.1954319
PMC: PMC13669672
Zhong D, Li C, Xiao Z • Frontiers in immunology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fimmu.2026.1938564
PMC: PMC13697605
Biazzo M, Soriani M, Micallef MP, Zaky E et al. • Microorganisms
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3390/microorganisms14102147
PMC: PMC13707607
Liu B, Wang L, Ma Y, Xu W et al. • Frontiers in immunology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fimmu.2026.1969637
PMC: PMC13714598
Han X, Yamashita K, Pizzi MP, Cho KS et al. • Journal for immunotherapy of cancer
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1136/jitc-2026-015653
PMC: PMC13723904
Huang J, Zhong H, Li L, Wang X et al. • Frontiers in oncology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fonc.2026.1962391
PMC: PMC13724477
Li L, Wu M, Li L • Frontiers in immunology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fimmu.2026.1950362
PMC: PMC13728787
Chen Y, Hou L • Oncology research
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.32604/or.2026.091624
PMC: PMC13732341
Katja Niesel, Michael Schulz, Julian Anthes, Tijna Alekseeva et al. • EMBO Molecular Medicine
(2021)
Abstract The tumor microenvironment in brain metastases is characterized by high myeloid cell content associated with immune suppressive and cancer‐permissive functions. Moreover, brain metastases induce the recruitment of lymphocytes. Desp...
DOAJ
Open Access (DOAJ)
DOI: 10.15252/emmm.202013412
Shuping Wang, Pengcheng Chen, Xiaozhen Jing, Jinglin Zou et al. • Materials & Design
(2026)
STING agonist-based immunotherapy holds considerable promise for cancer treatment, yet its efficacy against immunologically “cold” tumors such as lung adenocarcinoma (LUAD) remains markedly limited. A major obstacle lies in the highly glyco...
DOAJ
Open Access (DOAJ)
DOI: 10.1016/j.matdes.2026.117182
Jing Ma, Ruijuan Ma, Xueke Zeng, Liming Zhang et al. • Journal of Experimental & Clinical Cancer Research
(2023)
Abstract Background Platinum-drugs based chemotherapy in clinic increases the potency of tumor cells to produce M2 macrophages, thus leading to poor anti-metastatic activity and immunosuppression. Lysosome metabolism is critical for cancer ...
DOAJ
Open Access (DOAJ)
DOI: 10.1186/s13046-023-02768-0
Yujun Cai, Gengjia Chen, Minzhao Lin, Bo Li et al. • Aggregate
(2024)
Abstract Nanodrugs capable of aggregating in the tumor microenvironment (TME) have demonstrated great efficiency in improving the therapeutic outcome. Among various approaches, the strategy utilizing electrostatic interaction as a driving f...
DOAJ
Open Access (DOAJ)
DOI: 10.1002/agt2.476
Sepideh Parvizpour, Jafar Razmara, Mohammad M. Pourseif, Yadollah Omidi • BioImpacts
(2019)
Introduction: Triple-negative breast cancer (TNBC) is an important subtype of breast cancer, which occurs in the absence of estrogen, progesterone and HER-2 receptors. According to the recent studies, TNBC may be a cancer testis antigen (CT...
DOAJ
Open Access (DOAJ)
DOI: 10.15171/bi.2019.06
Bin Zhao, Sa Chen, Ye Hong, Liangliang Jia et al. • Pharmaceutics
(2022)
The conventional cancer therapeutic modalities include surgery, chemotherapy and radiotherapy. Although immunotherapy and targeted therapy are also widely used in cancer treatment, chemotherapy remains the cornerstone of tumor treatment. Wi...
DOAJ
Open Access (DOAJ)
DOI: 10.3390/pharmaceutics14071522
Qiang Fu, Qiang Fu, Qiang Fu, Fan Yang et al. • Frontiers in Oncology
(2019)
Post-transplant (post-Tx) kidney cancer has become the second-highest cause of death in kidney recipients. Late diagnosis and treatment are the main reasons for high mortality. Further research into early diagnosis and potential treatment i...
DOAJ
Open Access (DOAJ)
DOI: 10.3389/fonc.2019.00737